



**Groundbreaking Innovation in
Regenerative Medicine**

**HUMACYL™
HAV (Human Acellular Vessel)**

Image Courtesy of Duke University


HUMACYL: Regenerative Medicine Comes To Life

- **Acellular, human biological matrix products**
- **Readily available “off-the-shelf” replacements**
- **Highly innovative technology, many product possibilities**



An Implanted Bioengineered Human Vessel
Designed to Become the Patient's Own and
Last Longer with Fewer Complications

Groundbreaking Innovation in Regenerative Medicine



Affects of Going IPO Too Soon

Tengion Inc.
OTC: TNGNQ

Set Alerts

Find a Broker

Join TD Ameritrade

Market Index:

Enter Symbols or Keywords

GO

OVERVIEW PROFILE NEWS CHARTS FINANCIALS HISTORICAL QUOTES ANALYST ESTIMATES OPTIONS SEC FILINGS INSIDERS

Market open —Quotes are delayed by 20 min

Jan 26, 2016, 9:30 a.m.

Previous close

\$ 0.0003

Day low

\$0.0003

Day high

\$0.0003

52 week low

\$0.0003

52 week high

\$0.0034

\$0.0003

0.00 0.00%
Volume 500

10a 11a 12p 1p 2p 3p

Advanced Charts

Interactive Charts

Chart Controls

Symbol: TNGNQ

GO

Reset Chart

Timeframe

Display

Price Display

Scale

Trendlines & Notes

OHLC

HLC



CONFIDENTIAL


4

HUMACYTE

Public vs. Private?



Broad International Investor Base



CONFIDENTIAL

6

- Credit Suisse acted as sole banker on the transaction
- Brady Dougan, former Credit Suisse CEO, sits on Humacyte's Board



Humacyte Raises \$150M Series B

Top Private Single Funding Round in NC History

TRIANGLE BUSINESS JOURNAL

Triangle Business Journal
Huge fundraiser: RTP's Humacyte takes in
\$150M from private investors
October 20, 2015
By Jason deBruyn

PRIVATE EQUITY & VENTURE CAPITAL

VentureWire
Humacyte Secures \$150M Series B, Plans Phase III Clinical Trials

FORTUNE

Term Sheet -- Tuesday, October 20
October 20, 2015
Dan Primack
Humacyte, a Morrisville, N.C.-based
developer of human tissue-based
products for application in regenerative
medicine and vascular surgery, has
raised \$150 million in Series B funding.

BIOWORLD™ TODAY

THE DAILY BIOPHARMACEUTICAL NEWS SOURCE

BioWorld Today
Humacyte clinches \$150M B round for human acellular
vessel
October 21, 2015
By Amanda Pedersen

MORNINGS with MARIA

Fox Business News – Morning with Marie
Investing in the future of regenerative medicine
October 20, 2015
Maria Bartiromo



The News&Observer

The News & Observer RTP-based Humacyte raises
\$150M financing round
October 20, 2015
By David Bracken
Highlights

PE HUB

PE Hub
Humacyte snaps up \$150 mln Series B,
names Sebelius to board
October 20, 2015
By Iris Dorbian

